Good Evolution of Bicuspid Valves with EVOLUTE or EVOLUTE PRO

Courtesy of Dr. Carlos Fava.

TAVR has matured over time and has advanced onto low risk patients, but one of its greatest challenges continues to be bicuspid valve patients. These represent between 1% and 2% of the population and over 20% of young adults requiring surgical valve replacement (SAVR). 

Válvula Bicúspide

The study looked at 27,086 patients from the STS/ACC TVT REGISTRY undergoing TAVR with EVOLUTE or EVOLUTE PRO between July 2015 and September 2018. 932 had bicuspids (3.44%) and the rest had tricuspid valves.

Patients with bicuspid valves were younger (72 vs. 81 years old), mostly men, with fewer comorbidities and lower STS score (5.3±4.2% vs. 6.9±4.8% p<0.001).

In addition, they presented a bigger annulus and higher mean gradient with no differences in aortic valve area. 

To make homogeneous groups, patients were matched with Propensity Score, which left 929 pairs in each group.


Read also: SAPIEN 3: Good Outcomes in Bicuspids.


There were no differences in procedure. 92% received a femoral approach, 58% received general anesthesia, procedural success was similar and mean hospital stay was two days, with no differences in in-hospital mortality, stroke, pacemaker need, coronary obstruction, or vascular complications. 

At 30 days and one year, there were no differences between bicuspid and tricuspid patients as regards all-cause mortality (2.6% vs. 1.7%; p=0.18 and 3.9% vs. 4.4%; p=0.93), stroke (3.4% vs. 2.7%; p=0.41 and 3.9% vs. 4.4%; p=0.93), coronary obstruction, major bleeding or pacemaker implantation.

Reintervention rate was higher at 30 days and one year in the bicuspid group (0.8% vs. 0.1%; p =0.03 and1.7% vs. 0.3%; p= 0.01).


Read also: TAVR Reaches Low-Risk Patients with Bicuspid Valves.


Hemodynamic profile was similar, area was 1.9 cm2 and gradient was slightly higher at 30 days in bicuspids, with no differences at one year. Moderate to severe aortic regurgitation was higher at 30 days among bicuspid patients (5.6% vs. 2.1%; p < 0.001). The EVOLUTE PRO presented less moderate to severe regurgitation. There were no differences between bicuspid and tricuspid patients in mild regurgitation at 30 days (2.2% vs.1.5% p=0.71).

Both groups improved functional class and quality of life with no differences. 

Conclusion

There were no differences in all-cause mortality, stroke or hemodynamic profile at 30 days and 12 months. Patients presenting an intermediate risk for surgery, TAVR in severe aortic stenosis in bicuspid valves showed acceptable safety and low risk of complications. 

Courtesy of Dr. Carlos Fava.

Original Title: Transcatheter Aortic Valve Replacement in Bicuspid Versus Tricuspid Aortic Valves From the STS/ACC TVT Registry.

Reference: John K. Forrest, et al. J Am Coll Cardiol Intv 2020;13:1749-59.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Pathology of Self-Expanding Transcatheter Aortic Bioprostheses and Hypoattenuated Leaflet Thickening

Courtesy of Dr. Juan Manuel Pérez. Despite the available long term followup data on of transcatheter aortic valve replacement (TAVR), bioprosthesis durability continues under debate....

FRANCE TAVI Registry: Coronary Adverse Events After TAVI

Between 30% and 70% of patients undergoing transcatheter aortic valve implantation (TAVI) have coronary artery disease (CAD). However, the prognostic impact of CAD in...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...